Skip to main content

Systemic Diseases

We are working on autoimmune diseases (AID) and autoinflammatory disorders. We study the role of immune cells, cytokines and autoantibodies and their relationship with recurrent pregnancy loss and placental-related disorders. We aim to include animal models and trophoblast organoids in our research. The relationship between myositis, systemic sclerosis and cancer, as well as different autoantibody profiles, were analysed. We also studied the development of AID in oncologic patients treated with checkpoint inhibitors. Gene-wide genetic and molecular signatures studies in systemic vasculitis, Sjögren syndrome and systemic sclerosis are currently undergoing. We described a new risk haplotype for developing autoimmune/granulomatous disorders in patients with bioimplants. Our latest research line focuses on the study of immune mechanisms involved in thrombosis in COVID-19 in patients with and without antiphospholipid antibodies, as well as, its relationship with long-COVID.

eCORE

  • Woman & Child Health & Rare Diseases

Team

Group Leader
Jaume Alijotas Reig

Principal Investigator (PI)
Victoria Cardona Dahl, Moisés Labrador Horrillo, Albert Selva O'Callaghan, Carmen Pilar Simeón Aznar, Mª Roser Solans Laqué, Francesc Miró Mur

Researchers
Enrique Esteve Valverde, Albert Gil Vila, Mar Guilarte, Alfredo Guillén del Castillo, Olga Luengo, Fernando Martínez Valle, Jaume Mestres Torres, Josep Pardos Gea, Anna Sala Cunill

PhD Students
Ariadna Anunciación Llunell, Joana Marques Soares

Lab Technicians
Laura Donaire Lancharro, Nataria Pozuelo Ventura

Publications

75
Publications
50.7
%Q1
617.58
Impact Factor
8.23
Average Impact Factor

Alijotas-Reig J, Anunciación-Llunell A, Morales-Pérez S, Trapé J, Esteve-Valverde E, Miro-Mur F.
Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity.
Biomedicines. 2023 Aug 18;11(8):2301
DOI: 10.3390/biomedicines11082301
IF: 4.7

Kandhaya-Pillai R, Miro-Mur F, Alijotas-Reig J, Tchkonia T, Schwartz S, Kirkland JL, Oshima J.
Key elements of cellular senescence involve transcriptional repression of mitotic and DNA repair genes through the p53-p16/RB-E2F-DREAM complex.
Aging (Albany NY). 2023 May 22;15(10):4012-4034.
DOI: 10.18632/aging.204743.
IF: 5.2

Pinal-Fernàndez I, Milisenda JC, Pak K, Muñoz-Braceras S, Casal-Dominguez M, Torres-Ruiz J, Dell'Orso S, Naz F, Gutierrez-Cruz G, Duque-Jaimez Y, Matas-Garcia A, Padrosa J, Garcia-Garcia FJ, Guitart-Mampel M, Garrabou G, Trallero-Araguás E, Walitt B, Paik JJ, Albayda J, Christopher-Stine L, Lloyd TE, Grau-Junyent JM, Selva-O'Callaghan A, Mammen AL.
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies.
Ann Rheum Dis. 2023 Aug; 82(8):1091-1097.
DOI: 10.1136/ard-2023-223873.
IF: 27.4

Casal-Dominguez M, Pinal-Fernandez I, Pak K, Muñoz-Braceras S, Milisenda JC, Torres-Ruiz J, Dell Orso S, Naz F, Gutierrez-Cruz G, Duque-Jaimez Y, Matas-Garcia A, Valls-Roca L, Garrabou G, Trallero-Araguas E, Walitt B, Christopher-Stine L, Lloyd TE, Paik JJ, Albayda J, Corse A, Grau JM, Selva-O'Callaghan A, Mammen AL.
Coordinated local RNA overexpression of complement induced by interferon gamma in myositis.
Sci Rep. 2023 Feb 4; 13(1):2038
DOI: 10.1038/s41598-023-28838-z.
IF: 4.6

Sousa-Pinto B, Schünemann HJ, Sá-Sousa A, Vieira RJ, Amaral R, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann DE, Okamoto Y, Ventura MT, Agache I, Ansotegui IJ, Bergmann KC, Bosnic-Anticevich S, Canonica GW, Cardona V
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.
Allergy. 2023 Apr;78(4):968-983
DOI: 10.1111/all.15574
IF: 12.4

Projects

Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional
Principal Investigator: Albert Selva-O'Callaghan
Agency: Instituto de Salud Carlos III - PI22/00708
Funding: 135,000 €
Period: 2023-2025

‘Estudio de expresión de antígenos en tejido tumoral de pacientes con Esclerosis Sistémica
Principal Investigator: Carmen Pilar Simeón Aznar
Agency: Instituto de Salud Carlos III - PI22/01804
Funding: 75,020 €
Period: 2023-2025

Design of an integrative patients stratification approach for the systemic sclerosis management
Principal Investigator: Alfredo Guillén del Castillo
Agency: Fundación la Marató de TV3
Funding: 72,250 €
Period: 2022-2024

Investigating the role of gut microbiota-derived metabolism in modulating immune-cell functions as a potential “second hit” in the development of the antiphospholipid syndrome
Principal Investigator: Jaume Alijotas Reig, Francesc Miró Mur
Agency: Private funding
Funding: 330,000 €
Period: 2023-2026

Role of monocytes in obstetric complication related to antiphospholipid anntibodies.
Principal Investigator: Jaume Alijotas Reig, Francesc Miró Mur
Agency: Private Funding
Funding: 150,000 €
Period: 2021-2024

Patents

METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DEVELOP ASIA SYNDROME
Priority Number: EP23382738.5
Priority Date: 19/07/2023
Applicants: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA / BSURE MEDICAL

VHIR Annual Report 2023